Ah. Kulier et al., SUBCUTANEOUS RECOMBINANT-HUMAN-ERYTHROPOIETIN AND AUTOLOGOUS BLOOD DONATION BEFORE CORONARY-ARTERY BYPASS-SURGERY, Anesthesia and analgesia, 76(1), 1993, pp. 102-106
Conventional therapies with recombinant human erythropoietin (rHuEPO)
to sustain preoperative autologous blood collection entail high doses
of the drug at short intervals. To evaluate the efficacy of a single w
eekly dose of rHuEPO for autologous blood collection, we randomly assi
gned 24 male patients scheduled for coronary artery bypass surgery to
receive 400 IU/kg rHuEPO subcutaneously once a week or iron only Patie
nts were examined weekly and a total of up to 4 units of autologous bl
ood were obtained if the hemoglobin level exceeded 12 g/dL. Patients r
eceiving rHuEPO had consistently higher hemoglobin values than those r
eceiving iron only (P < 0.001). Consequently, more autologous red cell
s were obtained from this group (776 +/- 49 mL vs 682 +/- 91 mL; P < 0
.05). One patient receiving rHuEPO and eight in the control group requ
ired homologous blood at surgery (P < 0.01). These results suggest tha
t 400 IU/kg rHuEPO administered subcutaneously once a week efficiently
stimulates erythropoiesis and compensates the hemoglobin decrease aft
er autologous blood donation.